[Pubmed] Therapeutic development towards T follicular helper cells as a molecular target in myasthenia gravis disease
Posté : 10 déc. 2024 12:00
J Neuroimmunol. 2024 Dec 5;399:578503. doi: 10.1016/j.jneuroim.2024.578503. Online ahead of print.
ABSTRACT
This review intends to gather literature to provide a comprehensive understanding of the molecular mechanisms and role of T follicular helper cells (Tfh) in the interaction with germinal centers (GCs) in Myasthenia Gravis (MG) disease regarding new developments focusing on Tfh as a therapeutic target and its key regulator B cell lymphoma 6 (Bcl6). Tfh cells are CD4+ T cells specialized in providing signals for the activation and maturation of B cells plus the formation and maintenance of GCs; the role of Bcl6 stands as the key transcriptional factor for the survival of GCs and promotion of Tfh generation. Previous studies have demonstrated gene therapy to be beneficial by achieving re-establishment of "immune homeostasis" and amelioration of the proinflammatory process.
PMID:39657358 | DOI:10.1016/j.jneuroim.2024.578503
Source: https://pubmed.ncbi.nlm.nih.gov/3965735 ... t9+e462414